UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000040282
Receipt No. R000045959
Scientific Title Health economics-based verification of functional myocardial ischemia evaluation of stable coronary artery disease
Date of disclosure of the study information 2020/05/01
Last modified on 2020/05/01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Health economics-based verification of functional myocardial ischemia evaluation of stable coronary artery disease
Acronym Health economics-based verification of functional myocardial ischemia evaluation of stable coronary artery disease
Scientific Title Health economics-based verification of functional myocardial ischemia evaluation of stable coronary artery disease
Scientific Title:Acronym Health economics-based verification of functional myocardial ischemia evaluation of stable coronary artery disease
Region
Japan

Condition
Condition stable coronary artery disease
Classification by specialty
Cardiology Vascular surgery
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To contribute to the appropriate elective percutaneous coronary intervention (PCI), this study evaluate the health economics of testing and diagnosis for stable coronary artery disease (stable CAD) as long-term longitudinal study.
Basic objectives2 Others
Basic objectives -Others long-term clinical outcomes and cumulative public medical costs
Trial characteristics_1 Others
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes The primary endpoint is cost-effectiveness analysis (CEA).
Key secondary outcomes The secondary endpoints are major adverse coronary events (MACEs) or life years (LYs unit: year) and medical costs. CEA was the ratio of the related medical costs for over 36 months and LYs (US$/LY).

Base
Study type Others,meta-analysis etc

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
100 years-old >
Gender Male and Female
Key inclusion criteria This study identified a stable CAD in the subjects for analysis from the database using information including age when treatment was received, main disease (International Classification of Diseases 10th Revision: ICD-10), and treatment history. Out of ICD-10 code I11.0 through I50.9, eligibility criteria included patients with a disease code indicating stable CAD, adults aged 20 years or older, and patients undergoing testing or diagnosis related to the degree of anatomical coronary stenosis or functional ischemia severity for the first time: computed tomography angiography (CTA), stress myocardial perfusion imaging (MPI), coronary angiography (CAG), or coronary fractional flow reserve (FFR). Subjects were followed up for at least 1 year (excluding cases of mortality).
Key exclusion criteria The exclusion criteria were as follows: prior coronary revascularization, history of ACS within 1 year before the index day, and any latent risk factors that could affect the evaluation of cardiac disease diagnosis and treatment, such as cardiac-related surgery, assisted circulation or arrhythmia device implantation. We also excluded cases thought to have a low risk of cardiac disease. These included patients undergoing CTA alone for whom stress electrocardiogram (ECG) or stress echocardiography had not been performed within 1 year before the index day, patients undergoing CAG alone who had undergone the same testing two or more times (excluding follow-up CAG), and patients not treated with anti-platelet agents within 6 months after CAG (excluding cases considered to have no coronary stenosis). Patients who underwent coronary revascularization within 5 days after the index day were excluded because they were considered to have a very high risk of coronary disease and/or to be high priority emergency cases. Patients with concurrent systemic diseases, including malignant tumors or Kawasaki disease (sequela), as well as general injuries, were excluded because these factors could affect prognosis and medical costs.
Target sample size 3500

Research contact person
Name of lead principal investigator
1st name Tomoyuki
Middle name
Last name Takura
Organization The University of Tokyo
Division name Department of Healthcare Economics and Health Policy, Graduate School of Medicine,
Zip code 113-8655
Address 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
TEL +81-3-5800-9523
Email ttakura@m.u-tokyo.ac.jp

Public contact
Name of contact person
1st name Tomoyuki
Middle name
Last name Takura
Organization The University of Tokyo
Division name Department of Healthcare Economics and Health Policy, Graduate School of Medicine,
Zip code 113-8655
Address 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
TEL +81-3-5800-9523
Homepage URL http://plaza.umin.ac.jp/hehp/thebd.html
Email acishea@gmail.com

Sponsor
Institute Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The University of Tokyo
Institute
Department

Funding Source
Organization The University of Tokyo
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Tokyo Hospital IRB
Address 7-3-1, Hongo, Bunkyo-ku, Tokyo
Tel 03-5841-0818
Email acishea@gmail.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 東京大学附属病院

Other administrative information
Date of disclosure of the study information
2020 Year 05 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 3500
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2019 Year 03 Month 26 Day
Date of IRB
2019 Year 03 Month 26 Day
Anticipated trial start date
2020 Year 01 Month 07 Day
Last follow-up date
2020 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information This retrospective cohort study used a large database obtained from the public medical insurance system of Japan. The data source comprised medical economic big data that mainly included medical service bills gathered from public insurers (health insurance societies of companies and so on) throughout Japan (TheBD). We examined the medical service received at hospitals, clinics, and pharmacies between April 2012 and March 2019 based on therapy performed (testing/diagnosis, pharmacotherapy, treatment/surgery, hospitalized recuperation, and so on), outcomes (death, hospital transfer, and so on), and medical costs and chronologically linked subjects with unified IDs.

An analysis of related testing combinations was performed after dividing subjects into groups depending on whether or not functional myocardial ischemia was evaluated and considering the degree of invasiveness. Specifically, we broadly divided subjects into the anatomical and functional evaluation groups and also categorized subjects according to whether they entered the catheterization laboratory. Subjects were divided into the following groups according to the modality: those who only underwent CTA, those who underwent only CAG or, in some cases, CAG and CTA, those who underwent only MPI or, in some cases, MPI and CTA, and a those who underwent either CAG and FFR or MPI and CAG.

The bias related to patient backgrounds was reduced as much as possible using propensity score. For PS, we applied a multiple logistic regression analysis model using backward stepwise regression to predict dependent factors with functional ischemia evaluation being performed described as 1 and not being performed described as 0. To identify explanatory factors (covariance), we calculated PS for each case as sex, age/disease/pharmacotherapy/risk factors and matched the sample size with greedy matching. We then confirmed data distribution and balance for both groups (detailed testing of summary statistics per group).

Management information
Registered date
2020 Year 05 Month 01 Day
Last modified on
2020 Year 05 Month 01 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045959

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.